Focus on Lipids Care

Back to articles

ATP III Adds Millions of Americans to Treatment Categories

KEY POINT

The first revision in 8 years to federal guidelines on hypercholesterolemia management uses a complex formula to calculate Americans’ risk for coronary heart disease (CHD) or CHD events. The net result is millions of additional people (an increase from 13 million to 36 million) have a renewed focus on their elevated lipid levels, and pharmacists are in a prime position to offer guidance based on the recommendations in the Adult Treatment Panel III (ATP III) prepared by the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.

SOURCES

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

McKenney JM. New guidelines for managing hypercholesterolemia. J Am Pharm Assoc. 2001;41(Jul/Aug). In press.

Bluml BM et al. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc. 2000;40:157–65. 

Talbert RL. Lipid management by pharmacists: evidence of benefits [editorial]. J Am Pharm Assoc. 2000;40:143–4.

Pearson TA et al. The Lipid Treatment Assessment Project (L-TAP). Arch Intern Med. 2000;160:459–67.